Clinical research company IQVIA (NYSE: IQV) reported Q4 CY2025 results , with sales up 10.3% year on year to $4.36 billion.

The growth of AI agents creates increased demand for Okta’s services. The stock is a buy.

Detailed price information for Regal Rexnord Corp (RRX-N) from The Globe and Mail including charting and trades.